Please login to the form below

Not currently logged in
Email:
Password:

Storm Therapeutics bolsters its team

Professor Mark Dawson and Dr Paul Leeson join its scientific advisory board

UK-based drug discovery group Storm Therapeutics has strengthened its scientific advisory board with the addition of Professor Mark Dawson.

As a clinician-scientist at the University of Melbourne, Professor Dawson has experience in epigenetics having spent several years researching epigenetic regulation of leukaemia stem cells.

Dr Paul Leeson also joins the University of Cambridge spin-out, following 35 years’ experience of drug discovery and development in senior roles in pharmaceutical companies including GlaxoSmithKline, Merck Sharp and Dohme and AstraZeneca.

Keith Blundy, chief executive officer of Storm Therapeutics, said: “Mark’s expertise in epigenetics research will be invaluable as we advance selected targets into drug discovery, along with Paul’s long standing experience in drug discovery and development at big pharma will help Storm maximise the potential of our pipeline and harness the power of RNA epigenetics as a new area of important biology.”

3rd January 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...
MIT reveals new pill to deliver insulin
A new MIT research project, sponsored by Novo Nordisk, is aiming to deliver insulin orally with a pill that releases medicine in the stomach lining. Dina Patel interviews the team...
Fearless Girl cover
25 Women Leaders in UK Healthcare
Women trailblazers helping to shape the future of healthcare (Part 1)...

Infographics